Three Companies Race for Obesity Drug Approval
The race for an anti-obesity drug intensified Wednesday with the latest mid-stage trial data from Orexigen Therapeutics.
lorcaserin
VIVUS’ Qnexa Shows Promise For Diabetics
VIVUS, a pharmaceutical company specializing in products to treat sexual function, announced that their experimental obesity drug Qnexa was shown to improve blood sugar control in patients with type 2 diabetes.